CRISPR Therapeutics AG (CRSP) Stock Forecast & Price Target

CRSP price $54.87 +0.76 +1.40%

Ticker
CRSP
Price
$54.87
Change
+0.76 +1.40%
Market cap ?
$5.31B
P/E ?
-10.30
Forward P/E ?
12.41
Dividend yield ?
0.00%
Beta ?
1.76
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
40
Value
55
Quality
26
Growth
38

Stocklytics score rationale: value 55, quality 26, growth 38.

Financials

2016201720182019202020212022202320242025
5164000409970003124000289590000719000913081000436000370000000350000003510000

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates…

Forecast

Consensus Buy from 24 analysts. Average price target $63.17, +15.1% versus the current price. Low $52.00. High $80.00.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Analysts have an average 12-month price target of $63.17 for CRISPR Therapeutics AG (CRSP), 15.2% above the current price of $54.86. Of 24 analysts covering the stock, 14 rate it Buy or Strong Buy, 10 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.

Forecasts are third-party estimates and often wrong. They are not investment advice.

CRSP price target

12-month price target
Low$52.00
Average$63.17
High$80.00

The average is 15.2% above the current price of $54.86.

Is CRISPR Therapeutics AG a buy or sell?

Of 24 analysts, 14 rate CRISPR Therapeutics AG Buy or Strong Buy, 10 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.

CRISPR Therapeutics AG earnings and revenue forecast

Analyst averages on file: 2026, EPS -4.36, revenue $40.42 million. 2027, EPS -3.33, revenue $138.57 million.

CRSP score and fair value

The Stocklytics Score for CRSP is 40 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.

CRSP forecast FAQs

What is the CRSP price target?

$63.17 average, with a published range of $52.00 to $80.00.

Is CRISPR Therapeutics AG a buy or sell?

The consensus is Buy from 24 analysts. This is not a recommendation.

What is the CRISPR Therapeutics AG stock forecast for 2026?

Analysts' average EPS estimate for 2026 on file is -4.36. The average revenue estimate is $40.42 million.

What will CRSP be worth in 2030?

No reliable forecast exists that far out.

When is CRISPR Therapeutics AG's next earnings report?

The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.

Related: CRISPR Therapeutics AG · Financials · Dividends · Compare · AI stocks

Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.

CRISPR Therapeutics AG (CRSP) Stock Forecast & Price Target

CRSP$54.87+0.76 +1.40%

$5.31B

Market Cap

-10.30

P/E

12.41

Forward P/E

40

Score

Price History